Memory/active T cell activation is associated with immunotherapeutic response in fumarate hydratase-deficient renal cell carcinoma.
Junru ChenXu HuJunjie ZhaoXiaoxue YinLinmao ZhengJingjing GuoJianhui ChenYongquan WangXinan ShengHaiying DongXiaodong LiuXingming ZhangJiayu LiangHaolin LiuJin YaoZhenhua LiuYali ShenZhibin ChenZhengyu HeYaodong WangNi ChenLing NieMeng-Ni ZhangXiuyi PanYuntian ChenHaoyang LiuYaowen ZhangYanfeng TangSha ZhuJinge ZhaoJindong DaiZilin WangYuhao ZengZhipeng WangZhenlin HuangZhenhua LiuPeng-Fei ShenHao ZengGuangxi SunPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
ICI plus TKI combination therapy may represent a promising treatment option for metastatic FH-deficient RCC. A memory/active T cell-derived signature is associated with the efficacy of ICI+TKI but necessitates further validation.